{"id":24124,"date":"2024-09-16T13:41:00","date_gmt":"2024-09-16T17:41:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=24124"},"modified":"2026-04-08T09:42:02","modified_gmt":"2026-04-08T13:42:02","slug":"rems-the-regulatory-shield-blocking-affordable-generics","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/rems-the-regulatory-shield-blocking-affordable-generics\/","title":{"rendered":"REMS Abuse: How Brand Pharma Turned Patient Safety Rules Into a $5.4 Billion Competitive Weapon"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a weapon. For roughly a decade in the U.S. pharmaceutical industry, brand-name drug manufacturers discovered that this rule applied, with devastating effectiveness, to something nobody expected: government-mandated patient safety programs.<\/p>\n\n\n\n

Risk Evaluation and Mitigation Strategies, or REMS, were written into law in 2007 to solve a genuine problem. The FDA needed a formal, enforceable mechanism to allow powerful but dangerous drugs onto the market under conditions that minimized serious harm. The system worked as intended. Drugs that might have been too risky for general distribution could reach patients who truly needed them, because physicians, pharmacies, and patients operated inside a tightly controlled safety framework.<\/p>\n\n\n\n

The problem was that the same features making REMS effective at controlling patient risk also made them extraordinarily effective at controlling market access. Brand manufacturers who sponsored these programs found themselves holding the keys to a closed distribution system that every would-be generic competitor was legally required to enter. The leap from ‘safety program administrator’ to ‘market-access gatekeeper’ turned out to require very little imagination.<\/p>\n\n\n\n

This article examines how that happened, how Congress eventually responded, and what the current landscape looks like for generic and biosimilar manufacturers trying to navigate the aftermath. It draws on regulatory filings, court records, congressional testimony, academic literature, and competitive intelligence gathered through platforms like DrugPatentWatch<\/strong> to provide a comprehensive, practitioner-level analysis. The story is not entirely one of villains and victims, though there are elements of both. It is primarily a story about how a regulatory design flaw, compounded by financial incentives large enough to fund small countries, produced consequences that nobody who drafted the Food and Drug Administration Amendments Act of 2007 intended.<\/p>\n\n\n\n

Understanding these dynamics is no longer optional for professionals in generic or biosimilar development. It is table stakes for portfolio decisions, launch planning, and resource allocation. The patient safety language is just the surface. Underneath it is a set of legal, strategic, and financial calculations that will determine whether your drug makes it to market in this decade or the next.<\/p>\n\n\n\n

\n\n\n\n

What REMS Actually Are, and Why the Distinction Between Types Matters Enormously<\/strong><\/h2>\n\n\n\n

Before examining how the program was exploited, it helps to be precise about what it is. REMS is not a single, uniform intervention. It is a family of regulatory tools that spans from relatively simple information delivery all the way to comprehensive, closed-loop distribution controls. The anticompetitive potential is almost entirely concentrated in the most restrictive tier.<\/p>\n\n\n\n

From RiskMAPs to Mandated Controls: The Legislative Power of the FDAAA of 2007<\/strong><\/h3>\n\n\n\n

The FDA had been experimenting with voluntary risk management frameworks for years before 2007. The predecessor program, Risk Minimization Action Plans (RiskMAPs), gave the agency a framework for structuring risk-reduction measures but lacked mandatory enforcement authority. The participating company could, at least in theory, walk away from the arrangement.<\/p>\n\n\n\n

That changed on September 27, 2007, when Congress enacted the Food and Drug Administration Amendments Act (FDAAA). Section 505-1 of the Food, Drug, and Cosmetic Act gave the FDA explicit statutory authority to require a REMS from any drug manufacturer whose product posed a known serious risk [1]. The authority applied both to new applications and to drugs already on the market when new safety information emerged. Products with existing RiskMAPs that included the most restrictive controls were automatically deemed to have REMS in effect and were required to submit formal proposals for FDA approval.<\/p>\n\n\n\n

The FDAAA specified six factors the agency should consider when deciding whether to mandate a REMS [7]:<\/p>\n\n\n\n

    \n
  1. The estimated size of the patient population.<\/li>\n\n\n\n
  2. The seriousness of the disease or condition being treated.<\/li>\n\n\n\n
  3. The drug’s expected benefit.<\/li>\n\n\n\n
  4. Expected treatment duration.<\/li>\n\n\n\n
  5. The seriousness of known or potential adverse events.<\/li>\n\n\n\n
  6. Whether the drug qualifies as a new molecular entity.<\/li>\n<\/ol>\n\n\n\n

    This structure is rational. It concentrates the most demanding requirements on situations where the safety risks are genuinely severe. But the statute also contained language that would later become the grounds for prolonged legal battles. The FDAAA explicitly stated that any ETASU requirement must not be ‘unduly burdensome on patient access’ and must ‘to the extent practicable, minimize the burden on the health care delivery system’ [7]. Brand manufacturers defending their use of REMS against generic competitors would invoke the necessity of restrictive controls. Generic companies and patient advocates challenging those restrictions would invoke the ‘unduly burdensome’ language. Both sides could point to the same text. The collision was inevitable.<\/p>\n\n\n\n

    The Spectrum of REMS Components: From Pamphlets to Choke Points<\/strong><\/h3>\n\n\n\n

    A REMS can consist of as few as one component or as many as several interlocking requirements. The FDA tailors the specific elements to the nature and severity of the associated risk.<\/p>\n\n\n\n

    Medication Guides<\/strong> are patient-facing documents written in plain language and dispensed with the prescription [13]. They flag serious risks, describe what patients should watch for, and explain critical instructions for safe use. These are the lightest touch in the REMS toolkit. They do not restrict the supply chain; they inform it.<\/p>\n\n\n\n

    Communication Plans<\/strong> are directed at healthcare providers rather than patients [2]. They typically involve formal letters or educational materials circulated to prescribers and pharmacists, often through professional societies. The goal is to ensure that clinical staff understand a drug’s risk profile and the specific precautions required.<\/p>\n\n\n\n

    Both Medication Guides and Communication Plans are informational in nature. They create no physical barriers. A generic manufacturer can obtain the brand drug for bioequivalence testing without any interaction with these components, because they do not govern the supply chain. As a result, they offer essentially no lever for anticompetitive manipulation.<\/p>\n\n\n\n

    The competitive dynamics change completely with Elements to Assure Safe Use.<\/p>\n\n\n\n

    ETASU: The High-Control Tier That Created the Problem<\/strong><\/h3>\n\n\n\n

    Elements to Assure Safe Use are mandatory medical interventions or operational requirements that must be satisfied before a drug can be prescribed or dispensed [12]. They are reserved for drugs with known serious risks that cannot be adequately managed through standard labeling. The FDA’s rationale is that for certain drugs, prescribing and dispensing decisions need to be structured inside a formal control system rather than left to the judgment of individual providers.<\/p>\n\n\n\n

    ETASU can require some combination of the following [12]:<\/p>\n\n\n\n

      \n
    • Healthcare provider training and certification before a provider is authorized to prescribe the drug.<\/li>\n\n\n\n
    • Pharmacy certification, requiring dispensing sites to register and comply with specific protocols.<\/li>\n\n\n\n
    • Restricted administration settings, limiting dispensing to hospitals or infusion centers that have demonstrated they can manage serious adverse events.<\/li>\n\n\n\n
    • Documentation of safe-use conditions before each dispensing event, such as a confirmed negative pregnancy test for severely teratogenic drugs.<\/li>\n\n\n\n
    • Regular patient monitoring, such as periodic lab tests to detect early signs of organ toxicity.<\/li>\n\n\n\n
    • Patient enrollment in a registry that tracks outcomes and adverse events.<\/li>\n<\/ul>\n\n\n\n

      The design logic is sound. For a drug like thalidomide, where a single dose taken at the wrong point in pregnancy can cause catastrophic birth defects, a closed system that requires confirmation of contraceptive use before each prescription is dispensed represents a proportionate response to a demonstrated, severe risk [18].<\/p>\n\n\n\n

      But the architecture of that closed system gives the brand manufacturer something no drug company had previously possessed: a government-sanctioned reason to control who gets the drug at all. That control is the foundation on which the anticompetitive strategies were built.<\/p>\n\n\n\n

      The following table illustrates the scope and specificity of ETASU requirements across several major drugs:<\/p>\n\n\n\n

      Drug (Brand)<\/strong><\/th>Sponsor<\/strong><\/th>Indication<\/strong><\/th>Risk Addressed<\/strong><\/th>ETASU Requirements<\/strong><\/th><\/tr><\/thead>
      Vigabatrin (Sabril)<\/td>Lundbeck<\/td>Refractory Seizures, Infantile Spasms<\/td>Permanent Vision Loss<\/td>Prescriber\/pharmacy certification; patient enrollment; periodic vision assessment [15]<\/td><\/tr>
      Isotretinoin (iPLEDGE)<\/td>Multiple<\/td>Severe Nodular Acne<\/td>Severe Teratogenicity<\/td>Full prescriber\/pharmacy\/patient registration; monthly pregnancy tests [20]<\/td><\/tr>
      Lenalidomide (Revlimid)<\/td>Celgene\/BMS<\/td>Multiple Myeloma, MDS<\/td>Embryo-fetal Toxicity; Hematotoxicity<\/td>Prescriber\/pharmacy certification; patient registry; pregnancy tests [18]<\/td><\/tr>
      Thalidomide (Thalomid)<\/td>Celgene\/BMS<\/td>Multiple Myeloma, ENL<\/td>Embryo-fetal Toxicity; Thromboembolism<\/td>Prescriber\/pharmacy certification; patient registry; pregnancy tests [18]<\/td><\/tr>
      Riociguat (Adempas)<\/td>Bayer<\/td>Pulmonary Arterial Hypertension<\/td>Teratogenicity<\/td>Prescriber\/pharmacy certification; monthly pregnancy testing [18]<\/td><\/tr>
      Sodium Oxybate (Xyrem)<\/td>Jazz Pharmaceuticals<\/td>Narcolepsy<\/td>CNS\/Respiratory Depression; Abuse Potential<\/td>Prescriber certification; patient enrollment; single centralized pharmacy [18]<\/td><\/tr>
      Natalizumab (Tysabri)<\/td>Biogen<\/td>Multiple Sclerosis, Crohn’s<\/td>Progressive Multifocal Leukoencephalopathy<\/td>Prescriber\/infusion center\/patient enrollment in TOUCH program [18]<\/td><\/tr>
      Clozapine (Clozaril)<\/td>Multiple<\/td>Treatment-Resistant Schizophrenia<\/td>Severe Agranulocytosis<\/td>Prescriber\/pharmacy\/patient enrollment; regular blood monitoring (eliminated Feb. 2025) [18]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Each of these programs represents a legitimate clinical rationale. The issue is not the programs themselves. The issue is what happened when brand manufacturers realized these programs gave them an instrument they had never had before.<\/p>\n\n\n\n

      \n\n\n\n

      Why Generic Drug Approval Requires Physical Access to the Brand Product<\/strong><\/h2>\n\n\n\n

      To understand the leverage that REMS with ETASU gave brand manufacturers, you need to understand the one thing a generic developer cannot do without.<\/p>\n\n\n\n

      The Hatch-Waxman Framework: A Grand Bargain Built on Open Supply<\/strong><\/h3>\n\n\n\n

      The Drug Price Competition and Patent Term Restoration Act of 1984, universally known as Hatch-Waxman, is the structural foundation of the modern U.S. generic drug industry [27]. The law struck a deliberate balance. Brand manufacturers received patent term extensions and data exclusivity periods to compensate for time spent in regulatory review. Generic manufacturers received an expedited approval pathway that let them avoid duplicating expensive clinical trials already conducted by the brand company.<\/p>\n\n\n\n

      That expedited pathway is the Abbreviated New Drug Application, or ANDA. The core concept is straightforward: if a drug has already been proven safe and effective for a given indication, a second manufacturer should not have to run another 10-year clinical trial to prove the same thing. Instead, the generic manufacturer demonstrates that its version of the drug is pharmaceutically equivalent to the original and that it delivers the active ingredient to the bloodstream at the same rate and to the same extent, a standard called bioequivalence [28].<\/p>\n\n\n\n

      The elegance of this system carries an obvious dependency. Bioequivalence is a comparison. You cannot demonstrate that product A behaves like product B without having samples of product B. For most drugs, this is not a problem. The generic company buys the reference listed drug (RLD) through normal wholesale channels, exactly like any other purchaser. The transaction is routine and commercially unremarkable.<\/p>\n\n\n\n

      The Collision Course: 1984 Law Meets 2007 Regulation<\/strong><\/h3>\n\n\n\n

      Hatch-Waxman was designed in a world where approved drugs were freely available on the market. The architects of the law predicated the entire generic approval pathway on that assumption. It did not occur to them to write rules about what happens when the brand manufacturer controls access to its own product through a restricted distribution system, because no such system existed in 1984.<\/p>\n\n\n\n

      Twenty-three years later, the FDAAA created exactly that scenario. The most stringent REMS programs with ETASU established closed distribution networks as a matter of patient safety. Those networks are controlled by the brand manufacturer who holds the REMS. A generic company that wants to conduct bioequivalence testing using the RLD as the comparator now has to obtain that product through a system run entirely by the company whose market it intends to enter [27].<\/p>\n\n\n\n

      This is the structural vulnerability that brand manufacturers exploited. They did not need to do anything dramatic. They simply had to say no. The generic company’s approval process stopped cold. Without samples, there is no bioequivalence study. Without a bioequivalence study, there is no ANDA. Without an ANDA, there is no generic drug. One word, legally defensible as a safety concern, could preserve a monopoly for years.<\/p>\n\n\n\n

      Dr. Janet Woodcock, then-director of FDA’s Center for Drug Evaluation and Research, put it plainly in congressional testimony: the sample blockade was ‘a problem we struggle with a lot’ and had definitively ‘delayed availability of generics’ [33]. Her colleague Dr. John Jenkins stated that brand companies had ‘gone to the extent of kind of abusing the system’ and that REMS had ‘become an evergreening system for avoiding generic competition’ [33]. These were not outsiders making accusations. These were FDA officials describing what they observed from their regulatory vantage point.<\/p>\n\n\n\n

      \n\n\n\n

      Three Tactics: How Brand Manufacturers Converted REMS Into Market Protection<\/strong><\/h2>\n\n\n\n

      The exploitation of REMS took three distinct forms, each with its own mechanism and legal complexity. They were not mutually exclusive. Brand manufacturers often deployed multiple strategies simultaneously, layering defense against generic competition the way a patent thicket layers legal exposure.<\/p>\n\n\n\n

      Tactic One: The Sample Blockade<\/strong><\/h3>\n\n\n\n

      The most direct approach was simply to refuse to sell the brand drug to generic developers who needed it for bioequivalence testing. Brand manufacturers justified this refusal on safety grounds: providing samples to a third party for testing purposes, they argued, would violate the terms of the FDA-approved REMS and potentially expose test participants to serious risk [25].<\/p>\n\n\n\n

      The argument has a superficial plausibility. The REMS was designed to ensure that the drug reaches only patients in a controlled setting with appropriate monitoring. A laboratory or clinical testing facility is not that setting, technically speaking. Brand manufacturers’ legal teams ran with this framing aggressively.<\/p>\n\n\n\n

      The problem with the argument, and the reason the FTC filed amicus briefs calling the practice potentially illegal, is that it confuses the letter of safety regulations with their purpose [38]. A clinical research organization conducting bioequivalence testing on adult healthy volunteers is not the same situation as a pharmacy dispensing a severely teratogenic drug to a patient of reproductive age without a pregnancy test. The risk profiles are categorically different. Using REMS language designed to protect vulnerable patient populations as a justification for denying samples to pharmaceutical developers is a category error that the brand companies knew perfectly well they were making.<\/p>\n\n\n\n

      Celgene’s Blockbuster Blockade<\/strong><\/h4>\n\n\n\n

      No case illustrates the sample blockade more starkly than Celgene’s handling of Revlimid (lenalidomide) and Thalomid (thalidomide). Both are among the most commercially successful oncology drugs in pharmaceutical history. Revlimid alone generated over $12 billion in global sales in 2021, the year before its first U.S. generic competition arrived [18].<\/p>\n\n\n\n

      Both drugs carry genuine and severe teratogenic risk. Thalidomide’s history as the cause of limb defects in thousands of children born in Europe in the 1950s and 1960s makes its restricted distribution requirements entirely defensible from a scientific standpoint. The REMS programs for both drugs require all prescriptions to flow through a tightly controlled system that includes mandatory pregnancy testing, prescriber certification, and pharmacy certification.<\/p>\n\n\n\n

      Celgene used these legitimate safety requirements as the basis for refusing to sell samples to generic manufacturers, including Mylan (now Viatris), for years. When Mylan sued, the litigation laid out a comprehensive pattern of behavior: sample refusal was just one element of a broader scheme that also included patents on REMS processes and strategic settlement agreements with other potential competitors [38]. The lawsuit alleged that this conduct had cost patients and payers billions of dollars in foregone generic competition. The case settled confidentially, but the structural dynamic it revealed shaped the subsequent legislative response.<\/p>\n\n\n\n

      Actelion’s Preemptive Strike<\/strong><\/h4>\n\n\n\n

      Actelion took a more aggressive approach with its pulmonary arterial hypertension drug Tracleer (bosentan). Rather than simply refusing to sell samples and waiting to be sued, Actelion filed a preemptive lawsuit against would-be generic manufacturers Apotex and Roxane Laboratories, asking a federal court to declare that it had no legal obligation to sell them samples [25].<\/p>\n\n\n\n

      The filing in 2011 was a calculated move. It shifted the burden of proof and framed the entire dispute as a question of legal interpretation rather than corporate behavior. Generic companies found themselves defending against a lawsuit instead of pressing their own claims. The case settled confidentially, but the delay it generated served Actelion’s commercial interests regardless of the legal merits.<\/p>\n\n\n\n

      FDA’s ‘Name and Shame’ Response<\/strong><\/h4>\n\n\n\n

      In 2014, the FDA took an unusual step and published a list of brand drug manufacturers it believed were using REMS as a pretext to block generic sample access [23]. This public naming was a signal that the agency took the problem seriously, but it was also an acknowledgment of the agency’s limitations. The FDA maintained that it lacked the statutory authority to compel the sale of samples. It could shame companies, but it could not force them to sell. That limitation was the gap that Congress eventually filled with the CREATES Act.<\/p>\n\n\n\n

      Tactic Two: The Shared System Filibuster<\/strong><\/h3>\n\n\n\n

      The FDAAA includes a provision requiring that when a brand drug with ETASU faces generic competition, both the brand and the generic manufacturer must work toward a single, unified REMS program covering all versions of the drug [41]. The policy objective is sensible: physicians and pharmacists should not have to navigate different sets of rules depending on whether a patient’s prescription is filled with the brand or a generic version.<\/p>\n\n\n\n

      In practice, this requirement handed the brand manufacturer another strategic tool. Because the FDA would not approve a generic ANDA until the shared system REMS was agreed upon and submitted, the brand company held a de facto veto over the timing of any generic launch. An uncooperative negotiating partner could delay market entry indefinitely without doing anything that appeared overtly anticompetitive.<\/p>\n\n\n\n

      The mechanics of the filibuster were elaborately mundane. Brand companies and their lawyers would raise complex indemnification and product liability questions that resisted resolution. They would dispute how the operational costs of the shared system should be allocated. They would insist on data confidentiality provisions that generic companies found unacceptable. They would request more information, schedule meetings, cancel meetings, and schedule more meetings. They were never quite cooperating, but they were never quite refusing to cooperate either [41].<\/p>\n\n\n\n

      The results were stark. A decade after the REMS program began, as of early 2018, only 10 of the 72 existing REMS programs had been successfully converted to shared systems [41]. The FDA sent letters to manufacturers expressing concerns about their delay tactics for at least four separate products. But the agency’s ability to compel timely negotiation was limited, and the brand manufacturers knew it.<\/p>\n\n\n\n

      Every month of delay meant another month of monopoly pricing. If negotiations could be stretched across years, the incremental revenue far exceeded any conceivable legal or reputational cost. The math was not complicated.<\/p>\n\n\n\n

      Tactic Three: Patenting the Safety Process<\/strong><\/h3>\n\n\n\n

      The most legally sophisticated approach involved the U.S. patent system. Brand manufacturers began obtaining patents not on the drug molecule itself, but on the specific operational processes they used to comply with their FDA-mandated REMS programs [24].<\/p>\n\n\n\n

      The targets for these patents were elements like the software systems managing patient registries, the specific workflow for verifying prescriber certification before dispensing, or the logistical architecture of a restricted distribution network. Celgene, for instance, obtained patents on the restricted distribution system underpinning the Thalomid REMS [24].<\/p>\n\n\n\n

      The consequence for generic manufacturers was a catch-22 of striking cynicism. To gain FDA approval, a generic company must implement a REMS program that achieves the same safety standards as the brand’s program. If the brand company has patented the specific methods used to achieve those standards, the generic company faces an impossible choice: implement a non-infringing approach that may not meet FDA requirements, or implement the required approach and face a patent infringement lawsuit [24].<\/p>\n\n\n\n

      Adding another layer, some of these REMS patents were listed in the FDA’s Orange Book, which is the official registry of patents associated with approved drug products. Under Hatch-Waxman, when a generic company challenges an Orange Book-listed patent, the brand manufacturer can file an infringement lawsuit that automatically triggers a 30-month stay on the generic’s approval [28]. The clock on that stay runs while the litigation proceeds, during which the brand continues to sell at monopoly prices.<\/p>\n\n\n\n

      The logic of this structure, when you follow it to its conclusion, is genuinely remarkable:<\/p>\n\n\n\n

        \n
      1. A federal agency mandates a safety program to protect public health.<\/li>\n\n\n\n
      2. The company implementing that program obtains a private patent monopoly on the compliance methods.<\/li>\n\n\n\n
      3. A competitor, legally required to implement similar safety measures, is sued for doing so.<\/li>\n\n\n\n
      4. A government-created patent system then delays the competitor’s approval for 30 months.<\/li>\n<\/ol>\n\n\n\n

        A 2024 study in peer-reviewed literature confirmed this was not a theoretical concern. Researchers analyzing REMS patent filings found systematic evidence of brand manufacturers patenting REMS-related processes and using those patents in ways that predictably delayed generic competition [24].<\/p>\n\n\n\n

        \n\n\n\n

        The Dollar Cost: Quantifying $5.4 Billion a Year in Foregone Savings<\/strong><\/h2>\n\n\n\n

        These tactics were not just regulatory maneuvering in the abstract. They had a concrete and calculable financial impact on the U.S. healthcare system. <blockquote> ‘The ongoing abuse of REMS and restricted distribution programs costs the U.S. health system $5.4 billion annually. This amount represents the annual lost savings for just forty products included in one analysis; additional products continue to become subject to REMS programs on an ongoing basis.’ [37] – Association for Accessible Medicines, citing Matrix Global Advisors research, 2014 <\/blockquote><\/p>\n\n\n\n

        The $5.4 billion figure comes from a July 2014 study conducted by Matrix Global Advisors on behalf of what is now the Association for Accessible Medicines [44]. Researchers identified 40 specific small-molecule drugs for which generic manufacturers reported that market entry was being actively blocked by REMS-based tactics. Using 2013 brand sales data, they modeled the savings that would have accrued if generic competition had been allowed to proceed on a normal timeline.<\/p>\n\n\n\n

        The model applied two figures well-established in health economics: a 75% price reduction for generics relative to brand-name equivalents, consistent with Congressional Budget Office estimates, and a 95% generic substitution rate once a generic becomes available, reflecting standard market dynamics [29].<\/p>\n\n\n\n

        The resulting $5.4 billion in annual foregone savings breaks down as follows [44]:<\/p>\n\n\n\n

          \n
        • $2.4 billion absorbed by private health insurance plans.<\/li>\n\n\n\n
        • $1.8 billion borne by federal government programs, primarily Medicare and Medicaid.<\/li>\n\n\n\n
        • $960 million paid directly out of pocket by patients.<\/li>\n\n\n\n
        • $240 million borne by state and local government payers.<\/li>\n<\/ul>\n\n\n\n

          These numbers deserve careful interpretation. The $5.4 billion figure is almost certainly a significant undercount of the problem’s actual scope, for several reasons.<\/p>\n\n\n\n

          First, the analysis was conducted in 2014 using data from 2013. Prescription drug spending, the number of REMS programs, and the value of specialty drugs subject to REMS have all grown substantially in the years since.<\/p>\n\n\n\n

          Second, the study covered only 40 drugs. The total population of drugs with REMS was larger even then, and it has continued to expand, particularly in the specialty and biologic categories where individual drug revenues can be enormous.<\/p>\n\n\n\n

          Third, the study’s authors explicitly noted that the methodology was conservative. They applied a generic price discount lower than many empirical studies actually observe once multiple generic competitors enter a market. When four or more generics compete, prices for some drugs fall to 5-10% of the brand price, not 25% [29].<\/p>\n\n\n\n

          The study also projected that for every $1 billion in biologic drug sales successfully protected from biosimilar competition through REMS-based tactics, approximately $140 million in potential savings was being lost [44]. Given that biologic drug sales in the U.S. now run into the hundreds of billions of dollars annually, that projection points toward a problem far larger than $5.4 billion.<\/p>\n\n\n\n

          What These Numbers Mean for Patients<\/strong><\/h3>\n\n\n\n

          The economic framing, while necessary, can obscure the human consequences. Drug prices are the primary driver of non-adherence to prescribed treatment. Surveys consistently find that roughly one in four adults taking prescription drugs struggle to afford them, and a meaningful proportion report skipping doses, taking smaller doses than prescribed, or not filling prescriptions at all to manage cost [45].<\/p>\n\n\n\n

          When REMS-based tactics delay a generic drug by two or three years, the patients who bear that cost are often those least able to absorb it: people with serious chronic diseases who take expensive medications daily, people whose insurance coverage is thin, and people who are retired or on fixed incomes. These are not marginal inconveniences. For some patients, years of brand-price payments for a drug that could have been available at 25% of the cost represents thousands of dollars a year out of pocket, and for some it means going without.<\/p>\n\n\n\n

          The economic and patient-access harms of REMS abuse are not separable. They are the same problem expressed in different units.<\/p>\n\n\n\n

          \n\n\n\n

          The CREATES Act: Congress Picks the Lock<\/strong><\/h2>\n\n\n\n

          By 2018, the evidence of systematic REMS abuse was extensive, well-documented, and undeniable. The FDA had named companies. The FTC had filed amicus briefs calling the conduct potentially illegal. Congress had held multiple hearings. Academic researchers had quantified the costs. Yet the problem persisted, because no law clearly gave generic manufacturers the right to sue for samples or compelled brand manufacturers to negotiate shared REMS systems in good faith.<\/p>\n\n\n\n

          The Creating and Restoring Equal Access to Equivalent Samples Act of 2019, signed into law on December 20, 2019, addressed that gap [5]. It was bipartisan legislation, which in the contemporary U.S. political environment is unusual enough to be worth noting. It passed with support from both parties in both chambers, reflecting the breadth of stakeholder agreement that the status quo was indefensible.<\/p>\n\n\n\n

          What the CREATES Act Actually Does<\/strong><\/h3>\n\n\n\n

          The Act operates through two primary mechanisms: a private right of action for sample access, and a restructured pathway for developing shared or comparable REMS systems.<\/p>\n\n\n\n

          The Private Right of Action: A 31-Day Clock<\/strong><\/h4>\n\n\n\n

          Before the CREATES Act, a generic manufacturer facing a sample blockade had no direct legal remedy. It could file an antitrust lawsuit, which was slow, expensive, and uncertain. It could petition the FDA, which had said it lacked authority to compel sales. Neither path offered a reliable or timely solution.<\/p>\n\n\n\n

          The Act created a new cause of action that generic and biosimilar developers can pursue directly in federal court [35]. The mechanics are straightforward:<\/p>\n\n\n\n

          The developer sends a formal written request to the brand manufacturer for a sufficient quantity of samples on ‘commercially reasonable, market-based terms.’ If the brand manufacturer fails to deliver within 31 days, the developer can file a civil action in federal court. Courts finding in the developer’s favor must order the brand to provide samples. The Act also mandates attorney’s fee awards for prevailing developers, which removes the financial disincentive that previously made litigation an unattractive option even when the legal case was strong. If the court finds the brand delayed without a ‘legitimate business justification,’ it can award monetary damages capped at the brand’s revenue from the product during the delay period [35].<\/p>\n\n\n\n

          The 31-day window is deliberately short. It eliminates the brand company’s ability to run out the clock through procedural delays. The fee-shifting provision ensures that the costs of enforcement fall on the party that forced the dispute, not the party that merely sought access to a product it was legally entitled to test.<\/p>\n\n\n\n

          The Covered Product Authorization: Neutralizing the Safety Argument<\/strong><\/h4>\n\n\n\n

          For drugs subject to REMS with ETASU, the Act incorporates an important procedural safeguard. Before a developer can seek samples under the Act, it must first submit its proposed bioequivalence testing protocols to the FDA and receive a Covered Product Authorization (CPA) [35].<\/p>\n\n\n\n

          The CPA is a formal FDA determination that the developer’s handling procedures are comparable to the brand’s REMS and that providing samples would not constitute a REMS violation [25]. It directly addresses the brand company’s core argument: that sample sales would compromise patient safety by introducing the drug into an uncontrolled setting.<\/p>\n\n\n\n

          Once the FDA has issued a CPA confirming that the developer’s protocols are adequate, the brand company can no longer invoke safety concerns as a justification for refusal. The government agency charged with protecting patient safety has already reviewed and approved the developer’s procedures. What remains, if the brand company still refuses, is a commercial decision dressed in safety language, which is precisely what the Act was designed to make illegal.<\/p>\n\n\n\n

          Breaking the Shared System Deadlock<\/strong><\/h4>\n\n\n\n

          The Act’s second major provision restructured the shared REMS negotiation process by eliminating the brand manufacturer’s veto power [6].<\/p>\n\n\n\n

          Prior to the Act, a generic developer was trapped in a negotiation with no alternative exit. The CREATES Act changed this by amending the statute to permit a generic developer to propose its own separate but comparable REMS program to the FDA, as an alternative to a shared system. The generic company is still encouraged to pursue a shared system and must attempt good-faith negotiation. But if the brand company proves uncooperative, the developer has a clear fallback: develop and submit its own compliant safety program, and let the FDA evaluate it on its own merits.<\/p>\n\n\n\n

          This single change restructured the negotiation’s game theory. The brand company’s ability to delay indefinitely through bad-faith negotiation depends entirely on the generic company having no alternative. Once that alternative exists, prolonged stonewalling loses its value. The rational strategy for the brand company becomes reaching a reasonable agreement quickly, because the alternative is having the FDA approve a competing REMS over their objections.<\/p>\n\n\n\n

          \n\n\n\n

          Assessing the Aftermath: Is the CREATES Act Working?<\/strong><\/h2>\n\n\n\n

          The evidence, assembled from multiple sources including industry surveys, FDA annual reports, and academic commentary, consistently points in one direction: the Act has been highly effective.<\/p>\n\n\n\n

          Sample Access: The Problem Has Largely Disappeared<\/strong><\/h3>\n\n\n\n

          A 2021 analysis by Michael Kades for the Washington Center for Equitable Growth, based on conversations with industry representatives across the generic sector, reached a striking conclusion: the longstanding problem of sample blockades had ‘entirely or almost entirely disappeared’ since the Act’s passage [52].<\/p>\n\n\n\n

          What makes this finding particularly interesting is that the formal legal process created by the Act has reportedly been used very rarely. Companies have not been flooding federal courts with CREATES Act claims. The deterrent effect of the law, rather than its litigation mechanics, did most of the work.<\/p>\n\n\n\n

          This is consistent with how effective regulatory enforcement often operates. The threat of swift, certain, and financially significant consequences changes corporate behavior before any lawsuit is filed. Brand manufacturers evaluated the new legal environment and concluded that the expected value of continuing to block sample access, which now included the risk of paying a competitor’s legal fees plus damages capped at their own revenue, was negative. Samples began flowing.<\/p>\n\n\n\n

          Shared Systems: Progress Finally Measurable<\/strong><\/h3>\n\n\n\n

          On the shared system front, the FDA’s Office of Generic Drugs reported in its 2020 annual report that within one year of the Act’s passage, the agency had approved shared protocols for two products and standalone generic protocols for a third [52]. That sounds modest in absolute terms, but in context it represents a pace of progress that was essentially absent in the decade before the law passed.<\/p>\n\n\n\n

          The CREATES Act did not solve every problem in this space. More complex disputes, particularly those involving patents on REMS processes, continue to generate litigation. But the most common and most damaging forms of abuse, the sample blockade and the negotiation filibuster, appear to have been substantially contained.<\/p>\n\n\n\n

          What the Act Got Right About Incentive Design<\/strong><\/h3>\n\n\n\n

          The CREATES Act succeeded because it accurately diagnosed where the incentive structures had broken down and applied targeted pressure at precisely those points.<\/p>\n\n\n\n

          The sample blockade persisted because blocking samples was low-risk for brand companies. The antitrust lawsuit a generic might file was slow, expensive, and might fail on the merits. The expected legal cost was manageable compared to the revenue value of the delay. The CREATES Act raised the cost of blocking by creating a fast, direct remedy with fee-shifting and damages. The calculus flipped.<\/p>\n\n\n\n

          The negotiation filibuster persisted because the brand company’s veto power in shared system negotiations was absolute. No alternative path existed. The CREATES Act created an alternative. Once the brand company could no longer guarantee indefinite delay by refusing to cooperate, the value of the strategy evaporated.<\/p>\n\n\n\n

          Neither change required a fundamental restructuring of the REMS program or any compromise of patient safety. The FDA still requires robust REMS programs for drugs that need them. The CREATES Act simply removed the commercial advantage that brand manufacturers had extracted from administering those programs.<\/p>\n\n\n\n

          \n\n\n\n

          The New Battlefield: Biosimilars and the Amplified Stakes<\/strong><\/h2>\n\n\n\n

          The CREATES Act addressed the most acute problems facing small-molecule generic developers. It applies equally to biosimilar manufacturers, who face structurally similar challenges with substantially higher stakes.<\/p>\n\n\n\n

          Why Biosimilar REMS Challenges Hit Harder<\/strong><\/h3>\n\n\n\n

          Biosimilars are drugs that are highly similar to complex biologic medicines derived from living organisms [53]. The regulatory pathway for biosimilar approval, established by the Biologics Price Competition and Innovation Act (BPCIA) of 2010, is more demanding than the ANDA pathway for small-molecule generics. Demonstrating biosimilarity requires a comprehensive ‘totality-of-the-evidence’ approach that can include analytical studies, animal pharmacology data, and clinical pharmacokinetic and pharmacodynamic studies. Full clinical efficacy trials may also be required in some cases [54].<\/p>\n\n\n\n

          This greater complexity has direct implications for REMS-related challenges. Development timelines are longer, meaning any delay caused by sample access problems or shared system negotiations compounds over more time and more invested capital. The quantity of reference product needed for testing may be larger than for small-molecule generics. And the financial exposure is greater because the development costs are higher.<\/p>\n\n\n\n

          Biologics are also, on average, far more expensive than small-molecule drugs. The potential savings from biosimilar competition are correspondingly larger. For a drug costing $50,000 to $100,000 per patient per year, even a 20-30% biosimilar discount represents enormous systemic savings. The Matrix Global Advisors study’s projection of $140 million in lost savings per $1 billion in blocked biologic sales understates the current scale of the problem given how much biologic drug revenues have grown since 2014 [44].<\/p>\n\n\n\n

          The Ambiguous Legal Landscape for Biosimilar Shared REMS<\/strong><\/h3>\n\n\n\n

          The statutory requirement for a single shared REMS, which the CREATES Act addressed for small-molecule generics, is less rigorous for biosimilars. The FDA recommends that reference product sponsors and biosimilar applicants collaborate on a shared system, but it is not a strict statutory mandate in the same way it is for ANDAs [58]. This creates a more ambiguous negotiating environment that, in some respects, is harder to resolve cleanly even with the CREATES Act’s provisions.<\/p>\n\n\n\n

          Brand biologic manufacturers have deployed both the sample blockade and REMS process patents against biosimilar developers. The 2021 analysis referenced above indicated that while sample access improved for small-molecule generics, the biosimilar space remained more contested [52]. For companies developing biosimilars of complex biologics with REMS, the CREATES Act provides important tools but does not fully eliminate the risk of strategic delay.<\/p>\n\n\n\n

          The stakes are particularly high for the nascent U.S. biosimilar market. Unlike Europe, which has had a mature biosimilar market for nearly two decades, the U.S. biosimilar landscape is still developing. Market penetration rates for biosimilars in some therapeutic categories remain well below European levels, partly because of the greater complexity of the U.S. regulatory and legal environment. Anything that further delays or discourages biosimilar development has disproportionate consequences here.<\/p>\n\n\n\n

          \n\n\n\n

          FDA’s Modernization Agenda: Standardization, Digital Integration, and Dynamic Lifecycle Management<\/strong><\/h2>\n\n\n\n

          Parallel to the legislative response from Congress, the FDA has been pursuing its own reform agenda for the REMS program. These efforts are not primarily about deterring anticompetitive behavior. They are about making the program more efficient, more consistent, and more integrated into the digital infrastructure of modern healthcare delivery. But some of these changes may have secondary effects that further reduce the opportunity for REMS abuse.<\/p>\n\n\n\n

          Structured Product Labeling: Making REMS Machine-Readable<\/strong><\/h3>\n\n\n\n

          As of December 28, 2022, all new and modified REMS documents must be submitted to the FDA in Structured Product Labeling (SPL) format [59]. SPL is a standardized, computable data format that allows REMS information to be processed and shared by health information technology systems, including electronic health records and pharmacy management software.<\/p>\n\n\n\n

          The long-term vision is to embed REMS requirements directly into clinical workflows. Instead of a prescriber consulting a separate REMS document to determine whether a patient meets prescribing criteria, the EHR system would surface that information automatically within the standard prescribing interface. Similarly, pharmacy systems would check REMS dispensing conditions in real time rather than relying on manual verification.<\/p>\n\n\n\n

          This transformation matters for competition in a way that may not be immediately obvious. When REMS requirements are encoded in standardized, transparent, machine-readable formats and integrated into common healthcare IT systems, they become less amenable to proprietary control. A brand manufacturer who has built a REMS around opaque, proprietary software systems and data formats has a greater practical ability to position that system as uniquely essential and difficult to replicate. Standardized, open formats make it easier for generic manufacturers to develop comparable REMS programs and demonstrate their functional equivalence to the FDA, directly supporting the CREATES Act’s alternative REMS pathway.<\/p>\n\n\n\n

          The FDA Is Now Willing to Eliminate REMS That No Longer Earn Their Keep<\/strong><\/h3>\n\n\n\n

          One of the more significant recent signals from the FDA is a willingness to eliminate or substantially modify REMS programs when clinical experience and data demonstrate that the original risk management justification no longer holds, or that the burden of the program outweighs its benefit.<\/p>\n\n\n\n

          The most prominent recent example is the clozapine REMS, eliminated in February 2025 [26]. Clozapine is one of the most effective antipsychotics available for treatment-resistant schizophrenia, but its REMS, which required regular blood monitoring to detect potentially fatal agranulocytosis, had long been criticized as a barrier to patient care. Psychiatrists argued that the administrative burden of the REMS deterred prescribers from using the drug even for patients who could benefit significantly from it. Following recommendations from an advisory committee and substantial advocacy from professional societies, the FDA eliminated the program entirely, concluding that the safety monitoring requirements could be handled through labeling and standard clinical practice.<\/p>\n\n\n\n

          The FDA also streamlined the REMS for CAR T-cell therapies, removing mandatory reporting requirements for cytokine release syndrome, a well-characterized side effect that oncology centers have become adept at managing [64]. As clinical familiarity with a drug’s risk profile matures, the case for retaining burdensome REMS requirements weakens.<\/p>\n\n\n\n

          This dynamic lifecycle approach has implications for competitive analysis. A drug that currently carries a complex REMS with ETASU may see that program modified or eliminated as clinical experience accumulates, potentially shifting the competitive landscape for generic or biosimilar development. Tracking these regulatory developments is increasingly important for portfolio planning.<\/p>\n\n\n\n

          \n\n\n\n

          The Strategic Playbook: Turning REMS Intelligence Into Competitive Advantage<\/strong><\/h2>\n\n\n\n

          For generic and biosimilar manufacturers, the most important takeaway from the history of REMS abuse is that regulatory risk management is now an inseparable part of competitive strategy. A drug’s REMS status is not a compliance footnote. It is a material variable that affects development timelines, litigation budgets, launch timing, and ultimately returns on investment.<\/p>\n\n\n\n

          REMS Assessment as Core Due Diligence<\/strong><\/h3>\n\n\n\n

          The standard due diligence process for evaluating a generic drug candidate has historically focused on two questions: When does the patent protection expire? Can we prove bioequivalence? Both questions remain necessary but are no longer sufficient.<\/p>\n\n\n\n

          A complete due diligence framework now requires a REMS assessment that addresses several additional questions:<\/p>\n\n\n\n

          Does the drug have a REMS? If so, what type? A Medication Guide-only REMS presents essentially no additional competitive hurdles. A REMS with ETASU requires deeper investigation.<\/p>\n\n\n\n

          Does the REMS include a restricted distribution system? If so, who controls it, and what is the history of sample access for this manufacturer?<\/p>\n\n\n\n

          Has the brand manufacturer patented any elements of the REMS program? Orange Book patent analysis should now routinely include process and method patents, not just compound and formulation patents.<\/p>\n\n\n\n

          What is the brand manufacturer’s litigation posture on REMS issues? A company that has previously filed preemptive lawsuits against generic developers, as Actelion did, or that has a history of protracted shared system negotiations, should be assessed as a higher-risk counterparty in future REMS interactions.<\/p>\n\n\n\n

          What is the FDA’s current regulatory attitude toward this particular REMS? Is the program stable, under review, or potentially subject to modification or elimination?<\/p>\n\n\n\n

          Answering these questions accurately requires access to integrated competitive intelligence that covers regulatory filings, patent databases, litigation records, and market data simultaneously.<\/p>\n\n\n\n

          Using DrugPatentWatch for REMS-Aware Competitive Intelligence<\/strong><\/h3>\n\n\n\n

          DrugPatentWatch<\/strong> provides exactly the kind of integrated, multi-source intelligence that a REMS-aware competitive strategy requires. The platform aggregates data from the FDA, the U.S. Patent and Trademark Office, federal court records, and international regulatory bodies, allowing analysts to build a comprehensive picture of a target drug’s competitive environment from a single source [69].<\/p>\n\n\n\n

          The practical workflow for a REMS-aware market entry analysis using a platform like DrugPatentWatch<\/strong> typically proceeds in four stages:<\/p>\n\n\n\n

          Stage 1: Identify high-value targets.<\/strong> Screen for drugs with substantial annual revenues whose key composition-of-matter patents are approaching expiration. This generates a shortlist of commercially attractive candidates [70]. DrugPatentWatch<\/strong> data allows this screening at scale, flagging opportunities across the entire pharmaceutical market rather than relying on manual tracking of individual drugs.<\/p>\n\n\n\n

          Stage 2: Assess the regulatory complexity layer.<\/strong> Cross-reference the shortlist against FDA data on approved REMS programs. Any candidate with a REMS with ETASU should be flagged for deeper review. The platform’s regulatory data integration allows this cross-referencing without requiring analysts to navigate multiple government databases manually.<\/p>\n\n\n\n

          Stage 3: Analyze the full patent and litigation landscape.<\/strong> For candidates that pass the initial screen, conduct a comprehensive patent portfolio analysis that explicitly includes process and method patents that might relate to REMS compliance procedures. Review the litigation history of the brand manufacturer, including any REMS-related lawsuits filed or received. This intelligence informs both the likelihood of a successful Paragraph IV challenge and the expected cost of any REMS-related litigation.<\/p>\n\n\n\n

          Stage 4: Develop realistic timeline and resource projections.<\/strong> Combine the patent expiration timeline with the REMS complexity assessment to project a realistic range of possible launch dates and associated costs. This information feeds directly into go\/no-go decisions, first-to-file strategy timing, and legal budget allocations [71].<\/p>\n\n\n\n

          DrugPatentWatch<\/strong> has specifically highlighted the strategic importance of first-mover advantage in the generic drug market, noting that the first generic entrant captures dominant market share that subsequent competitors rarely dislodge [72]. The first-to-file, first-to-succeed dynamic in generic competition means that the quality of pre-filing intelligence determines not just whether you enter the market, but whether you enter it profitably. REMS intelligence is now a mandatory input to that analysis.<\/p>\n\n\n\n

          Integrating the CREATES Act Into Your Legal Strategy<\/strong><\/h3>\n\n\n\n

          Generic and biosimilar developers should treat the CREATES Act as a standard component of their launch legal framework for any product with a REMS with ETASU.<\/p>\n\n\n\n

          Before submitting an ANDA or biosimilar application, the legal team should evaluate the likely behavior of the brand manufacturer based on historical conduct. If that manufacturer has a history of sample access issues or prolonged shared system negotiations, the development timeline should include an explicit assumption that CREATES Act procedures may need to be invoked, along with the associated cost and timeline implications.<\/p>\n\n\n\n

          The Covered Product Authorization process should be initiated early. Obtaining a CPA from the FDA before requesting samples from the brand manufacturer removes the primary legal defense that brand companies have historically used to justify refusal. Developers who have already obtained a CPA are in a significantly stronger legal position if the brand company still refuses to sell.<\/p>\n\n\n\n

          The 31-day clock built into the CREATES Act is a double-edged strategic tool. For generic developers, it creates urgency for brand companies to respond to sample requests. For brand companies evaluating their own compliance, it represents a relatively tight window to avoid litigation exposure. Both sides should structure their processes around this timeline.<\/p>\n\n\n\n

          \n\n\n\n

          Looking Ahead: The Regulatory Horizon and Remaining Vulnerabilities<\/strong><\/h2>\n\n\n\n

          The passage of the CREATES Act and the FDA’s modernization initiatives have materially improved the competitive environment for generic and biosimilar developers. But the landscape continues to evolve, and several areas remain vulnerable to strategic exploitation.<\/p>\n\n\n\n

          REMS Process Patents: The Unresolved Problem<\/strong><\/h3>\n\n\n\n

          The CREATES Act addressed sample access and shared system negotiations directly and effectively. It did not address the intellectual property dimension of REMS abuse with equivalent directness. Obtaining patents on REMS-related processes and listing them in the Orange Book to trigger 30-month stays remains a legally available strategy, and it has not been decisively constrained by either statute or case law.<\/p>\n\n\n\n

          The 2024 peer-reviewed analysis of REMS patents found that this tactic had been used across multiple drugs and product categories [24]. The full legal picture is complicated by ongoing debate about whether process patents that claim compliance with government-mandated safety programs meet patentability requirements, and whether listing them in the Orange Book is appropriate. These questions are being litigated in multiple venues, but resolution is not imminent.<\/p>\n\n\n\n

          For generic developers, this means that even after clearing the CREATES Act hurdles of sample access and shared system development, patent infringement litigation over REMS-related process patents can still generate significant delays. Building this risk into due diligence and legal budgets remains necessary.<\/p>\n\n\n\n

          Novel and Complex Therapies: Next-Generation REMS Risk<\/strong><\/h3>\n\n\n\n

          Cell and gene therapies, RNA-based medicines, and other novel modalities present new REMS risk profiles that will likely generate new ETASU requirements in coming years. These therapies often involve unprecedented biological mechanisms and side effect profiles that current risk management frameworks were not designed to handle.<\/p>\n\n\n\n

          As REMS programs are designed for these new drug classes, the same structural vulnerability that affected the first generation of REMS drugs will be present: brand manufacturers who control closed distribution systems for novel therapies will have the theoretical ability to use those systems to restrict competitor access. The FDA and Congress will need to apply the lessons of the 2007-2019 period proactively, designing any new risk management frameworks with explicit safeguards against the access restriction patterns that required a decade of litigation and legislation to correct.<\/p>\n\n\n\n

          International Dimensions<\/strong><\/h3>\n\n\n\n

          The REMS framework is a U.S. regulatory construct, but pharmaceutical competition is global. Biosimilar developers in particular often operate simultaneously across U.S., European, and other international markets, and the regulatory and IP environment varies significantly across jurisdictions. European authorities have generally taken a more aggressive stance on anticompetitive behavior in the pharmaceutical sector, and European drug pricing and market access frameworks differ materially from U.S. systems.<\/p>\n\n\n\n

          For international companies developing U.S. biosimilars, understanding how REMS-related challenges interact with global development strategies is increasingly important. A biosimilar program that runs into REMS-based delays in the U.S. market may have different options available in European or other international markets that can inform negotiating positions or litigation strategy in the U.S. context.<\/p>\n\n\n\n

          \n\n\n\n

          Key Takeaways<\/strong><\/h2>\n\n\n\n

          REMS are legitimate patient safety programs that were systematically exploited.<\/strong> The FDA’s Risk Evaluation and Mitigation Strategies program was designed to allow access to powerful drugs under controlled safety conditions. The most restrictive tier, Elements to Assure Safe Use (ETASU), created closed distribution systems that brand manufacturers used to deny generic competitors access to the drug samples required for bioequivalence testing.<\/p>\n\n\n\n

          Three distinct tactics drove the abuse.<\/strong> Brand companies used the sample blockade (refusing to sell drug samples), the shared system filibuster (blocking negotiations on unified REMS programs through deliberate delay), and REMS process patents (patenting compliance methods and listing them in the Orange Book to trigger 30-month litigation stays). These tactics were often deployed simultaneously.<\/p>\n\n\n\n

          The financial toll was measurable and enormous.<\/strong> A 2014 analysis estimated that REMS abuse cost the U.S. healthcare system $5.4 billion annually in foregone generic savings, a figure distributed across private insurers, federal programs, and patients themselves. This estimate is almost certainly understated relative to current market conditions [44].<\/p>\n\n\n\n

          The CREATES Act of 2019 solved the core problems.<\/strong> By creating a private right of action for sample access, incorporating the Covered Product Authorization process to neutralize safety-based refusal arguments, and allowing generic companies to develop their own comparable REMS programs instead of negotiating indefinitely with brand companies, the Act restructured the incentives that had enabled abuse. Evidence from industry surveys and FDA data suggests the Act achieved its goals primarily through deterrence rather than litigation [52].<\/p>\n\n\n\n

          Biosimilars face amplified versions of the same challenges.<\/strong> Higher development costs, greater sample requirements, and a less rigidly defined shared system framework mean that REMS-based delays are even more financially damaging for biosimilar developers than for small-molecule generic manufacturers. The CREATES Act applies to biosimilars, but the legal landscape remains more complex.<\/p>\n\n\n\n

          REMS assessment is now mandatory due diligence.<\/strong> Any generic or biosimilar developer evaluating a pipeline target must assess that drug’s REMS status, the brand manufacturer’s history of REMS-related conduct, the existence of REMS process patents, and the FDA’s current regulatory posture toward the program. Platforms like DrugPatentWatch<\/strong> provide the integrated patent, regulatory, and litigation intelligence needed to conduct this assessment efficiently and accurately.<\/p>\n\n\n\n

          \n\n\n\n

          FAQ<\/strong><\/h2>\n\n\n\n

          Q1: How does the Covered Product Authorization process work, and how does it change the strategic dynamics of a CREATES Act sample request?<\/strong><\/p>\n\n\n\n

          The Covered Product Authorization (CPA) is a formal FDA determination, issued in letter form, confirming that a generic or biosimilar developer’s proposed procedures for handling, storing, and using drug samples in bioequivalence studies are comparable to the safety protections required under the brand’s REMS [25]. The developer submits its testing protocols to the FDA before requesting samples from the brand company.<\/p>\n\n\n\n

          The strategic value of the CPA is that it closes the brand company’s primary escape route. The argument that sample provision would violate the REMS or compromise patient safety is the standard justification that brand companies used for sample refusals prior to the CREATES Act. Once the FDA has reviewed and approved the developer’s handling procedures, the agency responsible for patient safety has already determined that the transaction is safe. A brand company that still refuses to sell at that point is making a commercial decision, not a safety one, and the CREATES Act’s damages provisions apply. This makes the CPA application a prerequisite step that developers should complete as early as possible in the ANDA or biosimilar development process.<\/p>\n\n\n\n

          Q2: Are REMS process patents listed in the Orange Book currently subject to any regulatory challenge beyond standard patent litigation?<\/strong><\/p>\n\n\n\n

          The listing of REMS process patents in the Orange Book has become an increasingly contested issue, and there are regulatory developments that may constrain the practice. The FDA finalized rules in 2024 that narrowed the categories of patents eligible for Orange Book listing. Specifically, the agency clarified that patents on drug delivery devices, and certain method patents, may not be appropriate for Orange Book listing depending on their scope and relationship to the approved drug product [24].<\/p>\n\n\n\n

          However, the specific question of whether REMS compliance method patents are appropriate for Orange Book listing remains somewhat unsettled in regulatory guidance and case law. The FTC has taken an increasingly active interest in Orange Book patent listing practices generally, having brought cases against companies it alleges improperly listed patents. Developers confronting Orange Book-listed REMS patents should consult patent counsel on both the validity of the listing and the viability of filing delisting petitions with the FDA as a complement to patent litigation strategy.<\/p>\n\n\n\n

          Q3: How does the FDA decide to eliminate or substantially modify a REMS program, and what signals should developers watch for?<\/strong><\/p>\n\n\n\n

          The FDA can initiate a REMS modification or elimination based on new safety data, post-market surveillance information, or an assessment that the burden of the program has come to outweigh its benefit. The agency may also act in response to an advisory committee recommendation, as occurred with clozapine, or in response to formal petitions from professional societies, patient advocacy groups, or other stakeholders [26].<\/p>\n\n\n\n

          Developers monitoring a target drug’s REMS for potential modification should track FDA advisory committee meetings scheduled for the relevant drug or drug class, published FDA perspectives on the REMS program, changes in clinical practice guidelines that might affect the regulatory justification for specific ETASU requirements, and post-market surveillance publications that update the known risk profile of the drug. A REMS elimination or significant modification can substantially change the competitive landscape for a generic or biosimilar target, either by removing a major operational complexity from development or by opening distribution channels that were previously restricted. DrugPatentWatch<\/strong> tracks FDA regulatory actions in ways that can support this kind of monitoring.<\/p>\n\n\n\n

          Q4: What specific provisions of the BPCIA make biosimilar REMS negotiations more legally ambiguous than the generic ANDA situation?<\/strong><\/p>\n\n\n\n

          Under the Hatch-Waxman Act framework for small-molecule generics, the statutory requirement for a single, shared REMS when a brand drug with ETASU faces generic competition is relatively clear, even if the practical mechanics of achieving that shared system proved exploitable before the CREATES Act [41]. The BPCIA, which governs biosimilar approval, does not contain an equivalent statutory mandate with the same level of specificity. The FDA recommends shared REMS for biosimilars but has somewhat more regulatory discretion in how it applies this recommendation in individual cases [58].<\/p>\n\n\n\n

          This ambiguity creates a negotiating environment where the expected outcome of a disagreement is less certain for both parties, which can actually make negotiations more contentious rather than less. Both the reference product sponsor and the biosimilar developer may have incentives to test the limits of the regulatory framework rather than accept terms they consider unfavorable. The CREATES Act’s alternative REMS pathway applies to biosimilars and provides an important check on brand company leverage, but the ambiguity in the underlying statutory framework means that this area continues to generate legal disputes that require careful navigation.<\/p>\n\n\n\n

          Q5: Beyond the CREATES Act, what additional policy tools have been proposed or implemented to address REMS-based competition barriers?<\/strong><\/p>\n\n\n\n

          Several additional policy approaches have been discussed or implemented at the federal and state levels. The FTC has expanded its pharmaceutical industry enforcement focus to include REMS-related conduct, and its 2023 policy statement on unfair methods of competition explicitly cited restrictions on competitor access to drug samples as potentially violative conduct [40]. This provides a direct antitrust enforcement pathway that complements the private right of action under the CREATES Act.<\/p>\n\n\n\n

          Some states have enacted or proposed legislation addressing drug sample access at the state level, drawing on the CREATES Act framework but extending it in various directions. The HHS drug pricing executive order implementation efforts from 2021 specifically identified REMS abuse as a priority concern for competitive policy [45]. On the patent front, proposals to require inter partes review of REMS-related Orange Book patents before the 30-month stay takes effect have been advanced in academic and policy contexts, though they have not yet been enacted into law. For biosimilars specifically, ongoing implementation of the BPCIA’s interchangeability framework and the FDA’s guidance on biosimilar substitution continue to shape the competitive environment in ways that intersect with REMS management.<\/p>\n\n\n\n

          \n\n\n\n

          References<\/strong><\/h2>\n\n\n\n

          [1] U.S. Food and Drug Administration. (2025). Risk evaluation and mitigation strategies (REMS)<\/em>. https:\/\/www.fda.gov\/drugs\/our-perspective\/risk-evaluation-and-mitigation-strategies-rems<\/p>\n\n\n\n

          [2] U.S. Food and Drug Administration. (n.d.). Risk evaluation and mitigation strategies (REMS) [Video]<\/em>. https:\/\/www.fda.gov\/drugs\/fda-drug-info-rounds-video\/risk-evaluation-and-mitigation-strategies-rems<\/p>\n\n\n\n

          [3] U.S. Food and Drug Administration. (n.d.). Standardizing and evaluating risk evaluation and mitigation strategies (REMS)<\/em>. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Standardizing-and-Evaluating-Risk-Evaluation-and-Mitigation-Strategies-(REMS).pdf<\/p>\n\n\n\n

          [5] Hogan Lovells. (n.d.). Key considerations for responding to a CREATES Act request<\/em>. https:\/\/www.hoganlovells.com\/en\/publications\/key-considerations-for-responding-to-a-creates-act-request<\/p>\n\n\n\n

          [6] ArentFox Schiff. (n.d.). Congress CREATES a new action to combat drug approval delays<\/em>. https:\/\/www.afslaw.com\/perspectives\/alerts\/congress-creates-a-new-action-to-combat-drug-approval-delays<\/p>\n\n\n\n

          [7] Legal Information Institute. (n.d.). 21 U.S. Code \u00a7 355-1: Risk evaluation and mitigation strategies<\/em>. https:\/\/www.law.cornell.edu\/uscode\/text\/21\/355-1<\/p>\n\n\n\n

          [12] PDR.net. (n.d.). REMS summary of terms<\/em>. https:\/\/www.pdr.net\/rems-summary-of-terms<\/p>\n\n\n\n

          [13] Becker, M., & Gold, R. (2020). Adaptation for regulatory application: A content analysis of FDA risk evaluation and mitigation strategies assessment plans (2014-2018) using RE-AIM<\/em>. BMC Health Services Research<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7052173\/<\/p>\n\n\n\n

          [15] U.S. Food and Drug Administration. (n.d.). Risk evaluation and mitigation strategies (REMS)<\/em>. https:\/\/www.fda.gov\/media\/105565\/download<\/p>\n\n\n\n

          [16] Association for Accessible Medicines. (n.d.). REMS abuse impeding patient access to generic drugs: Myths and facts<\/em>. https:\/\/accessiblemeds.org\/resources\/blog\/rems-abuse-impeding-patient-access-generic-drugs-myths-and-facts\/<\/p>\n\n\n\n

          [18] Bhatt, D. L., & Mehta, C. (2016). Risk evaluation and mitigation strategies (REMSs): Are they improving drug safety? A critical review of REMSs requiring elements to assure safe use (ETASU)<\/em>. PLOS ONE<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5427046\/<\/p>\n\n\n\n

          [20] Wikipedia. (n.d.). Risk evaluation and mitigation strategies<\/em>. https:\/\/en.wikipedia.org\/wiki\/Risk_Evaluation_and_Mitigation_Strategies<\/p>\n\n\n\n

          [23] Center for Biosimilars. (n.d.). FDA names companies that restrict access to drug samples for generic testing<\/em>. https:\/\/www.centerforbiosimilars.com\/view\/fda-names-companies-that-restrict-access-to-drug-samples-for-generic-testing<\/p>\n\n\n\n

          [24] Sachs, R. E., & Sherkow, J. S. (2024). Patents on risk evaluation and mitigation strategies for prescription drugs and generic competition<\/em>. PLOS Medicine<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10884947\/<\/p>\n\n\n\n

          [25] FDA Law Blog. (2015, January). New FDA draft guidance on REMS and bioequivalence studies<\/em>. https:\/\/www.fdalawblog.com\/2015\/01\/articles\/legislation\/new-fda-draft-guidance-on-rems-and-bioequivalence-studies-does-new-procedure-secure-anda-applicants-the-right-to-obtain-samples\/<\/p>\n\n\n\n

          [26] American Society of Health-System Pharmacists. (2025, February 27). FDA eliminates clozapine REMS program<\/em>. https:\/\/news.ashp.org\/news\/ashp-news\/2025\/02\/27\/fda-eliminates-clozapine-rems-program<\/p>\n\n\n\n

          [27] Congressional Research Service. (n.d.). FDA risk evaluation and mitigation strategies (REMS): Description and effect on generic drug development<\/em> (R44810). https:\/\/www.congress.gov\/crs-product\/R44810<\/p>\n\n\n\n

          [28] Sarpatwari, A., Avorn, J., & Kesselheim, A. S. (2019). Generic drugs in the United States: Policies to address pricing and competition<\/em>. PLOS Medicine<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6355356\/<\/p>\n\n\n\n

          [29] Congressional Budget Office. (1998, July). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry<\/em>. https:\/\/www.cbo.gov\/sites\/default\/files\/cbofiles\/ftpdocs\/6xx\/doc655\/pharm.pdf<\/p>\n\n\n\n

          [33] PBS NewsHour. (n.d.). Are drug companies using safety rules to block generic competition?<\/em> https:\/\/www.pbs.org\/newshour\/nation\/drug-companies-using-safety-rules-block-generic-competition<\/p>\n\n\n\n

          [35] Congressional Research Service. (n.d.). The CREATES Act of 2019 and lowering drug prices: Legal background and overview<\/em> (LSB10272). https:\/\/www.congress.gov\/crs_external_products\/LSB\/PDF\/LSB10272\/LSB10272.4.pdf<\/p>\n\n\n\n

          [37] Association for Accessible Medicines. (n.d.). Restricted access drug programs impeding patient access to generic drugs: Myths and facts regarding Maine LD 1280<\/em>. https:\/\/accessiblemeds.org\/resources\/blog\/restricted-access-drug-programs-impeding-patient-access-generic-drugs-myths-and\/<\/p>\n\n\n\n

          [38] Grabowski, H., Guha, R., & Salgado, M. (2016). Generics companies press for REMS relief: Potential law would clarify when brand-name manufacturers must supply drug samples<\/em>. Health Affairs<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5046996\/<\/p>\n\n\n\n

          [40] Patterson Belknap Webb & Tyler LLP. (n.d.). FTC competition director highlights enforcement priorities in the pharmaceutical industry<\/em>. https:\/\/www.pbwt.com\/antitrust-update-blog\/ftc-competition-director-highlights-enforcement-priorities-in-the-pharmaceutical-industry<\/p>\n\n\n\n

          [41] Commonwealth Fund. (2018, June). Anticompetitive efforts to block affordable drugs: A patient’s story and policy solutions<\/em>. https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2018\/jun\/anticompetitive-efforts-block-affordable-drugs-patients-story<\/p>\n\n\n\n

          [44] Matrix Global Advisors. (2014, July). Lost prescription drug savings from use of REMS programs to block generic drug market entry<\/em>. https:\/\/getmga.com\/wp-content\/uploads\/2022\/04\/REMS_Study_July.pdf<\/p>\n\n\n\n

          [45] U.S. Department of Health and Human Services, ASPE. (2021). Report to the White House Competition Council<\/em>. https:\/\/aspe.hhs.gov\/sites\/default\/files\/2021-09\/Competition%20EO%2045-Day%20Drug%20Pricing%20Report%209-8-2021.pdf<\/p>\n\n\n\n

          [52] Kades, M. (2021). The CREATES Act shows legislation can stop anticompetitive pharmaceutical industry practices<\/em>. Washington Center for Equitable Growth. https:\/\/equitablegrowth.org\/the-creates-act-shows-legislation-can-stop-anticompetitive-pharmaceutical-industry-practices\/<\/p>\n\n\n\n

          [53] Wikipedia. (n.d.). Biosimilar<\/em>. https:\/\/en.wikipedia.org\/wiki\/Biosimilar<\/p>\n\n\n\n

          [54] Congressional Research Service. (n.d.). Biologics and biosimilars: Background and key issues<\/em> (R44620). https:\/\/www.congress.gov\/crs-product\/R44620<\/p>\n\n\n\n

          [58] Center for Biosimilars. (n.d.). FDA issues 2 draft guidance documents on REMS programs<\/em>. https:\/\/www.centerforbiosimilars.com\/view\/fda-issues-2-draft-guidance-documents-on-rems-programs<\/p>\n\n\n\n

          [59] U.S. Food and Drug Administration. (2025). Risk evaluation and mitigation strategies (REMS)<\/em>. https:\/\/www.fda.gov\/drugs\/our-perspective\/risk-evaluation-and-mitigation-strategies-rems<\/p>\n\n\n\n

          [64] DIA Global Forum. (2025, June). Evolving REMS for complex therapies: Addressing safety in innovation<\/em>. https:\/\/globalforum.diaglobal.org\/issue\/june-2025\/evolving-rems-for-complex-therapies-addressing-safety-in-innovation\/<\/p>\n\n\n\n

          [69] Crozdesk. (n.d.). DrugPatentWatch: Software reviews and alternatives<\/em>. https:\/\/crozdesk.com\/software\/drugpatentwatch<\/p>\n\n\n\n

          [70] GreyB. (n.d.). Drug patent watch<\/em>. https:\/\/www.greyb.com\/services\/patent-search\/drug-patent-watch\/<\/p>\n\n\n\n

          [71] GeneOnline News. (n.d.). DrugPatentWatch highlights 5 strategies for generic drug manufacturers to succeed post-patent expiration<\/em>. https:\/\/www.geneonline.com\/drugpatentwatch-highlights-5-strategies-for-generic-drug-manufacturers-to-succeed-post-patent-expiration\/<\/p>\n\n\n\n

          [72] DrugPatentWatch. (n.d.). First generic launch has significant first-mover advantage over later generic drug entrants<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/first-generic-launch-has-significant-first-mover-advantage-over-later-generic-drug-entrants\/<\/p>\n","protected":false},"excerpt":{"rendered":"

          There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a […]<\/p>\n","protected":false},"author":1,"featured_media":24126,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-24124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=24124"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24124\/revisions"}],"predecessor-version":[{"id":37903,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24124\/revisions\/37903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/24126"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=24124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=24124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=24124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}